Business
Finalist for 2nd National Award for SSI reduction
Ondine Biomedical Inc. and Mid Yorkshire Teaching NHS Trust have been shortlisted for the Excellence in Healthcare Partnership Award for their work in reducing surgical site infections using nasal photodisinfection technology. This partnership's Steriwave intervention demonstrated a 71% reduction in post-surgical infections in hip surgery and no observed infections in knee surgery over a six-month period at two hospitals, highlighting its potential for patient safety and cost savings within the NHS. This marks the second national award shortlist for the collaboration, underscoring the effectiveness of photodisinfection as an alternative to antibiotics in preventing infections and addressing antimicrobial resistance. Disclaimer*
About this update from Ondine Biomedical, Inc.
[{"type":"text","content":"\n\n23 December 2025\nONDINE BIOMEDICAL INC.\n(\"Ondine Biomedical\", \"Ondine\" or the \"Company\")\nFinalist for 2nd National Award for SSI reduction\n Ondine and Mid Yorkshire Teaching NHS Trust shortlisted for Excellence in Healthcare Partnership Award for Reducing Surgical Site Infections with Nasal Photodisinfection\nSecond national award shortlist recognises successful partnership addressing the NHS priority of reducing surgical site infections and antimicrobial resistance.\nOndine Biomedical Inc (AIM: OBI) and Mid Yorkshire Teaching NHS Trust (Mid Yorks) are finalists for the 'Partnership Working to Address National Healthcare Priorities (Local Projects)' category at the prestigious 2026 Excellence in Healthcare Partnership (EHP) Awards.\nThis shortlisting recognises the successful collaboration between Ondine and Mid Yorks to address one of the NHS's most pressing challenges: reducing surgical site infections (SSIs) while limiting reliance on antibiotics. It follows the Trust's introduction of Ondine's Steriwave® nasal photodisinfection technology into orthopaedic surgery pathways at its Pontefract and Pinderfields hospitals.\nThis is the partnership's second recent selection for a national awards shortlist, underscoring nasal photodisinfection as an important infection-prevention and cost-saving approach for the NHS which can help address wait lists, currently exceeding six million patients. This recognition comes on the heels of being named a finalist for the HSJ Partnership Award in the category of 'Most Impactful Use of Technology on Clinical Practice'. \nImplemented for patients undergoing hip and knee replacement surgery at Mid Yorks' Pontefract and Pinderfields hospitals, the Steriwave intervention was associated with a 71% reduction in post-surgical infections in hip surgery over six months, with no SSIs observed in knee surgery during the evaluation period. In addition to improving patient outcomes, the initiative delivered meaningful cost savings by reducing avoidable complications and associated hospital resource use.\nThe EHP Awards specifically celebrate collaborations that align with national healthcare priorities, including patient safety, antimicrobial stewardship and system efficiency. The Ondine-Mid Yorks partnership demonstrates how clinically integrated innovation can deliver measurab...